Clinicopathological, radiologic, and molecular study of 23 combined hepatocellular-cholangiocarcinomas with stem cell features, cholangiolocellular type

Cholangiolocellular carcinoma is a type of intrahepatic cholangiocarcinoma (ICC). According to the 2010 World Health Organization classification, this carcinoma is a combined hepatocellular-cholangiocarcinoma with stem cell features, cholangiolocellular type (CHC-SC-CLC). The aim of this study was t...

Full description

Saved in:
Bibliographic Details
Published inHuman pathology Vol. 64; pp. 118 - 127
Main Authors Chen, Jun, He, Jian, Deng, Min, Wu, Hong-Yan, Shi, Jiong, Mao, Liang, Sun, Qi, Tang, Min, Fan, Xiang-Shan, Qiu, Yu-Dong, Huang, Qin
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.06.2017
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Cholangiolocellular carcinoma is a type of intrahepatic cholangiocarcinoma (ICC). According to the 2010 World Health Organization classification, this carcinoma is a combined hepatocellular-cholangiocarcinoma with stem cell features, cholangiolocellular type (CHC-SC-CLC). The aim of this study was to compare the clinicopathological characteristics of CHC-SC-CLC and conventional ICC. Based on the gross and histologic characteristics, we divided consecutive ICC tumors into CHC-SC-CLC (n = 23), mass-forming (MF; n = 57), and non-MF (n = 22) groups. Compared with MF and non-MF groups, the CHC-SC-CLC group featured history of hepatolithiasis or bile duct operation in significantly fewer patients (4.3% versus 14.8% and 86.4%, respectively; P < .001) and was more common in the right lobe (70% versus 47% and 27%; P = .033) but lower frequency of invasive growth or peritumoral Glisson sheath invasion (61% and 22% versus 77% and 33% and 100% and 86%, respectively; P = .002 and P < .001) and absence of mucous production (0 versus 77% and 96%; P < .001). In CHC-SC-CLCs, the mutation rate of isocitrate dehydrogenase 1 (IDH1) or IDH2 was significantly higher (35%) than in MF (4%) or non-MF (0) ICCs (P < .001). The 1-, 3-, and 5-year postresection survival rates were also significantly better with CHC-SC-CLCs (93%, 79%, and 52%, respectively) than with MF (72%, 46%, and 40%) or non-MF (61%, 18%, and 0) ICCs (P = .041). Thus, CHC-SC-CLC tumors demonstrated an indolent growth pattern, more frequent IDH1/2 gene mutations, and better prognosis than did MF or non-MF ICC tumors. •CHC-SC-CLC was commonly related to prior liver injury but not cholangiolithiasis or cholangitis.•CHC-SC-CLC demonstrated indolent growth characteristics, for example, fewer Glisson sheath invasions.•IDH1/2 mutations were detected in a third of CHC-SC-CLCs but few ICCs.•CHC-SC-CLC showed a better postresection prognosis than did ICC.
AbstractList Cholangiolocellular carcinoma is a type of intrahepatic cholangiocarcinoma (ICC). According to the 2010 World Health Organization classification, this carcinoma is a combined hepatocellular-cholangiocarcinoma with stem cell features, cholangiolocellular type (CHC-SC-CLC). The aim of this study was to compare the clinicopathological characteristics of CHC-SC-CLC and conventional ICC. Based on the gross and histologic characteristics, we divided consecutive ICC tumors into CHC-SC-CLC (n = 23), mass-forming (MF; n = 57), and non-MF (n = 22) groups. Compared with MF and non-MF groups, the CHC-SC-CLC group featured history of hepatolithiasis or bile duct operation in significantly fewer patients (4.3% versus 14.8% and 86.4%, respectively; P < .001) and was more common in the right lobe (70% versus 47% and 27%; P = .033) but lower frequency of invasive growth or peritumoral Glisson sheath invasion (61% and 22% versus 77% and 33% and 100% and 86%, respectively; P = .002 and P < .001) and absence of mucous production (0 versus 77% and 96%; P < .001). In CHC-SC-CLCs, the mutation rate of isocitrate dehydrogenase 1 (IDH1) or IDH2 was significantly higher (35%) than in MF (4%) or non-MF (0) ICCs (P < .001). The 1-, 3-, and 5-year postresection survival rates were also significantly better with CHC-SC-CLCs (93%, 79%, and 52%, respectively) than with MF (72%, 46%, and 40%) or non-MF (61%, 18%, and 0) ICCs (P = .041). Thus, CHC-SC-CLC tumors demonstrated an indolent growth pattern, more frequent IDH1/2 gene mutations, and better prognosis than did MF or non-MF ICC tumors. •CHC-SC-CLC was commonly related to prior liver injury but not cholangiolithiasis or cholangitis.•CHC-SC-CLC demonstrated indolent growth characteristics, for example, fewer Glisson sheath invasions.•IDH1/2 mutations were detected in a third of CHC-SC-CLCs but few ICCs.•CHC-SC-CLC showed a better postresection prognosis than did ICC.
Cholangiolocellular carcinoma is a type of intrahepatic cholangiocarcinoma (ICC). According to the 2010 World Health Organization classification, this carcinoma is a combined hepatocellular-cholangiocarcinoma with stem cell features, cholangiolocellular type (CHC-SC-CLC). The aim of this study was to compare the clinicopathological characteristics of CHC-SC-CLC and conventional ICC. Based on the gross and histologic characteristics, we divided consecutive ICC tumors into CHC-SC-CLC (n = 23), mass-forming (MF; n = 57), and non-MF (n = 22) groups. Compared with MF and non-MF groups, the CHC-SC-CLC group featured history of hepatolithiasis or bile duct operation in significantly fewer patients (4.3% versus 14.8% and 86.4%, respectively;P< .001) and was more common in the right lobe (70% versus 47% and 27%;P= .033) but lower frequency of invasive growth or peritumoral Glisson sheath invasion (61% and 22% versus 77% and 33% and 100% and 86%, respectively;P= .002 andP< .001) and absence of mucous production (0 versus 77% and 96%;P< .001). In CHC-SC-CLCs, the mutation rate of isocitrate dehydrogenase 1 (IDH1) orIDH2was significantly higher (35%) than in MF (4%) or non-MF (0) ICCs (P< .001). The 1-, 3-, and 5-year postresection survival rates were also significantly better with CHC-SC-CLCs (93%, 79%, and 52%, respectively) than with MF (72%, 46%, and 40%) or non-MF (61%, 18%, and 0) ICCs (P= .041). Thus, CHC-SC-CLC tumors demonstrated an indolent growth pattern, more frequentIDH1/2gene mutations, and better prognosis than did MF or non-MF ICC tumors.
Summary Cholangiolocellular carcinoma is a type of intrahepatic cholangiocarcinoma (ICC). According to the 2010 World Health Organization classification, this carcinoma is a combined hepatocellular-cholangiocarcinoma with stem cell features, cholangiolocellular type (CHC-SC-CLC). The aim of this study was to compare the clinicopathological characteristics of CHC-SC-CLC and conventional ICC. Based on the gross and histologic characteristics, we divided consecutive ICC tumors into CHC-SC-CLC (n = 23), mass-forming (MF; n = 57), and non-MF (n = 22) groups. Compared with MF and non-MF groups, the CHC-SC-CLC group featured history of hepatolithiasis or bile duct operation in significantly fewer patients (4.3% versus 14.8% and 86.4%, respectively; P < .001) and was more common in the right lobe (70% versus 47% and 27%; P = .033) but lower frequency of invasive growth or peritumoral Glisson sheath invasion (61% and 22% versus 77% and 33% and 100% and 86%, respectively; P = .002 and P < .001) and absence of mucous production (0 versus 77% and 96%; P < .001). In CHC-SC-CLCs, the mutation rate of isocitrate dehydrogenase 1 ( IDH1 ) or IDH2 was significantly higher (35%) than in MF (4%) or non-MF (0) ICCs ( P < .001). The 1-, 3-, and 5-year postresection survival rates were also significantly better with CHC-SC-CLCs (93%, 79%, and 52%, respectively) than with MF (72%, 46%, and 40%) or non-MF (61%, 18%, and 0) ICCs ( P = .041). Thus, CHC-SC-CLC tumors demonstrated an indolent growth pattern, more frequent IDH1/2 gene mutations, and better prognosis than did MF or non-MF ICC tumors.
Cholangiolocellular carcinoma is a type of intrahepatic cholangiocarcinoma (ICC). According to the 2010 World Health Organization classification, this carcinoma is a combined hepatocellular-cholangiocarcinoma with stem cell features, cholangiolocellular type (CHC-SC-CLC). The aim of this study was to compare the clinicopathological characteristics of CHC-SC-CLC and conventional ICC. Based on the gross and histologic characteristics, we divided consecutive ICC tumors into CHC-SC-CLC (n = 23), mass-forming (MF; n = 57), and non-MF (n = 22) groups. Compared with MF and non-MF groups, the CHC-SC-CLC group featured history of hepatolithiasis or bile duct operation in significantly fewer patients (4.3% versus 14.8% and 86.4%, respectively; P < .001) and was more common in the right lobe (70% versus 47% and 27%; P = .033) but lower frequency of invasive growth or peritumoral Glisson sheath invasion (61% and 22% versus 77% and 33% and 100% and 86%, respectively; P = .002 and P < .001) and absence of mucous production (0 versus 77% and 96%; P < .001). In CHC-SC-CLCs, the mutation rate of isocitrate dehydrogenase 1 (IDH1) or IDH2 was significantly higher (35%) than in MF (4%) or non-MF (0) ICCs (P < .001). The 1-, 3-, and 5-year postresection survival rates were also significantly better with CHC-SC-CLCs (93%, 79%, and 52%, respectively) than with MF (72%, 46%, and 40%) or non-MF (61%, 18%, and 0) ICCs (P = .041). Thus, CHC-SC-CLC tumors demonstrated an indolent growth pattern, more frequent IDH1/2 gene mutations, and better prognosis than did MF or non-MF ICC tumors.
Cholangiolocellular carcinoma is a type of intrahepatic cholangiocarcinoma (ICC). According to the 2010 World Health Organization classification, this carcinoma is a combined hepatocellular-cholangiocarcinoma with stem cell features, cholangiolocellular type (CHC-SC-CLC). The aim of this study was to compare the clinicopathological characteristics of CHC-SC-CLC and conventional ICC. Based on the gross and histologic characteristics, we divided consecutive ICC tumors into CHC-SC-CLC (n = 23), mass-forming (MF; n = 57), and non-MF (n = 22) groups. Compared with MF and non-MF groups, the CHC-SC-CLC group featured history of hepatolithiasis or bile duct operation in significantly fewer patients (4.3% versus 14.8% and 86.4%, respectively; P < .001) and was more common in the right lobe (70% versus 47% and 27%; P = .033) but lower frequency of invasive growth or peritumoral Glisson sheath invasion (61% and 22% versus 77% and 33% and 100% and 86%, respectively; P = .002 and P < .001) and absence of mucous production (0 versus 77% and 96%; P < .001). In CHC-SC-CLCs, the mutation rate of isocitrate dehydrogenase 1 (IDH1) or IDH2 was significantly higher (35%) than in MF (4%) or non-MF (0) ICCs (P < .001). The 1-, 3-, and 5-year postresection survival rates were also significantly better with CHC-SC-CLCs (93%, 79%, and 52%, respectively) than with MF (72%, 46%, and 40%) or non-MF (61%, 18%, and 0) ICCs (P = .041). Thus, CHC-SC-CLC tumors demonstrated an indolent growth pattern, more frequent IDH1/2 gene mutations, and better prognosis than did MF or non-MF ICC tumors.Cholangiolocellular carcinoma is a type of intrahepatic cholangiocarcinoma (ICC). According to the 2010 World Health Organization classification, this carcinoma is a combined hepatocellular-cholangiocarcinoma with stem cell features, cholangiolocellular type (CHC-SC-CLC). The aim of this study was to compare the clinicopathological characteristics of CHC-SC-CLC and conventional ICC. Based on the gross and histologic characteristics, we divided consecutive ICC tumors into CHC-SC-CLC (n = 23), mass-forming (MF; n = 57), and non-MF (n = 22) groups. Compared with MF and non-MF groups, the CHC-SC-CLC group featured history of hepatolithiasis or bile duct operation in significantly fewer patients (4.3% versus 14.8% and 86.4%, respectively; P < .001) and was more common in the right lobe (70% versus 47% and 27%; P = .033) but lower frequency of invasive growth or peritumoral Glisson sheath invasion (61% and 22% versus 77% and 33% and 100% and 86%, respectively; P = .002 and P < .001) and absence of mucous production (0 versus 77% and 96%; P < .001). In CHC-SC-CLCs, the mutation rate of isocitrate dehydrogenase 1 (IDH1) or IDH2 was significantly higher (35%) than in MF (4%) or non-MF (0) ICCs (P < .001). The 1-, 3-, and 5-year postresection survival rates were also significantly better with CHC-SC-CLCs (93%, 79%, and 52%, respectively) than with MF (72%, 46%, and 40%) or non-MF (61%, 18%, and 0) ICCs (P = .041). Thus, CHC-SC-CLC tumors demonstrated an indolent growth pattern, more frequent IDH1/2 gene mutations, and better prognosis than did MF or non-MF ICC tumors.
Author Deng, Min
Fan, Xiang-Shan
Sun, Qi
Chen, Jun
He, Jian
Shi, Jiong
Huang, Qin
Mao, Liang
Tang, Min
Wu, Hong-Yan
Qiu, Yu-Dong
Author_xml – sequence: 1
  givenname: Jun
  surname: Chen
  fullname: Chen, Jun
  organization: Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China
– sequence: 2
  givenname: Jian
  surname: He
  fullname: He, Jian
  organization: Department of Radiology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China
– sequence: 3
  givenname: Min
  surname: Deng
  fullname: Deng, Min
  organization: Department of Hepatopancreatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China
– sequence: 4
  givenname: Hong-Yan
  surname: Wu
  fullname: Wu, Hong-Yan
  organization: Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China
– sequence: 5
  givenname: Jiong
  surname: Shi
  fullname: Shi, Jiong
  organization: Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China
– sequence: 6
  givenname: Liang
  surname: Mao
  fullname: Mao, Liang
  organization: Department of Hepatopancreatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China
– sequence: 7
  givenname: Qi
  surname: Sun
  fullname: Sun, Qi
  organization: Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China
– sequence: 8
  givenname: Min
  surname: Tang
  fullname: Tang, Min
  organization: Department of Radiology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China
– sequence: 9
  givenname: Xiang-Shan
  surname: Fan
  fullname: Fan, Xiang-Shan
  email: fxs23@163.com
  organization: Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China
– sequence: 10
  givenname: Yu-Dong
  surname: Qiu
  fullname: Qiu, Yu-Dong
  email: yudongqiu510@163.com
  organization: Department of Hepatopancreatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China
– sequence: 11
  givenname: Qin
  surname: Huang
  fullname: Huang, Qin
  organization: Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28431889$$D View this record in MEDLINE/PubMed
BookMark eNqNkt-KEzEUh4OsuN3VR1AC3njRqUlmkplBdJHiP1jwQr0OaeZkm5pJusmMS9_ExzVja4WCrHAgBL7fx-Gcc4HOfPCA0FNKFpRQ8XKzWI_9Vg3rBSO0XhCaSzxAM8pLVjRly87QjJBKFA2t63N0kdKGEEp5xR-hc9ZUJW2adoZ-Lp31VofJFFy4sVq5OY6qs_vfHCvf4T440KNTEadh7HY4GMxKrEO_sh46vIYcDxqcm5hCZ5PyNzZoFbX1oVcJ39lhncPQ4wnDBtQwRkhzfITdUYCH3RYeo4dGuQRPDu8l-vb-3dflx-L684dPy7fXheaEDUVbcUWU7lRVm1YArAxnbEVa05iqBDCioxWUnJiSAm-JVoqWLQduuFi1XLDyEr3Ye7cx3I6QBtnbNHWiPIQxSdq0lFZNxUhGn5-gmzBGn7uTtKVMiKoWZaaeHahx1UMnt9H2Ku7kn5lngO8BHUNKEcwRoUROu5UbeditnHYrCc0lcu7VSU7bQQ02-CEq6-5NX-3TkIf5w0KUSVvwGjobQQ-yC_Zew5sTg_59O8p9hx2kv7OQiUkiv0zXNx0frct8eKLJgtf_FvxHA78AWwbwOg
CitedBy_id crossref_primary_10_1186_s40644_023_00621_3
crossref_primary_10_1038_s41379_019_0290_0
crossref_primary_10_3390_biomedicines10081826
crossref_primary_10_3390_cancers13122871
crossref_primary_10_1002_jmri_27553
crossref_primary_10_1007_s11901_020_00556_4
crossref_primary_10_1016_j_humpath_2017_12_028
crossref_primary_10_9738_INTSURG_D_18_00002_1
crossref_primary_10_1002_hep_29789
crossref_primary_10_1016_j_critrevonc_2022_103892
crossref_primary_10_1007_s11901_018_0431_9
crossref_primary_10_1016_j_compbiomed_2022_105520
crossref_primary_10_1111_hepr_13428
crossref_primary_10_1067_j_cpsurg_2018_10_002
crossref_primary_10_1186_s13578_023_01156_7
crossref_primary_10_1186_s40792_021_01120_y
crossref_primary_10_11569_wcjd_v27_i18_1114
crossref_primary_10_1016_j_hpb_2019_10_009
crossref_primary_10_4254_wjh_v16_i5_766
Cites_doi 10.1002/hep.25786
10.1200/JCO.2012.41.5984
10.1016/j.humpath.2011.12.007
10.1007/s11894-011-0178-8
10.1038/modpathol.2013.241
10.1200/JCO.2011.35.6519
10.1038/onc.2012.315
10.1002/hep.24351
10.1634/theoncologist.2011-0386
10.1245/s10434-014-3582-0
10.1007/s00595-014-1031-0
10.1016/j.surg.2008.11.010
10.1097/PAS.0000000000000579
10.1002/1097-0142(195907/08)12:4<753::AID-CNCR2820120420>3.0.CO;2-L
10.1002/hep.25595
10.1002/jhbp.154
10.1097/PAS.0b013e31827332b0
10.1097/00000478-199512000-00007
10.1016/j.jhep.2013.02.013
10.1002/hep.22238
10.1038/nature13441
ContentType Journal Article
Copyright 2017
Copyright © 2017. Published by Elsevier Inc.
Copyright Elsevier Limited Jun 1, 2017
Copyright_xml – notice: 2017
– notice: Copyright © 2017. Published by Elsevier Inc.
– notice: Copyright Elsevier Limited Jun 1, 2017
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
K9.
7X8
DOI 10.1016/j.humpath.2017.01.016
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitleList
ProQuest Health & Medical Complete (Alumni)


MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1532-8392
EndPage 127
ExternalDocumentID 28431889
10_1016_j_humpath_2017_01_016
S0046817717301168
1_s2_0_S0046817717301168
Genre Journal Article
Comparative Study
GroupedDBID ---
--K
--M
.1-
.55
.FO
.GJ
.~1
0R~
1B1
1CY
1P~
1RT
1~.
1~5
3O-
4.4
457
4CK
4G.
53G
5GY
5RE
5VS
7-5
71M
8P~
9JM
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQOH
AAQQT
AAQXK
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABFRF
ABJNI
ABLJU
ABMAC
ABMZM
ABWVN
ABXDB
ACDAQ
ACGFO
ACGFS
ACIEU
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADFRT
ADMUD
ADNMO
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFFNX
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGUBO
AGYEJ
AHHHB
AHMBA
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
BPHCQ
BVXVI
CAG
COF
DU5
EBS
EFJIC
EFKBS
EJD
EMOBN
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HDY
HMK
HMO
HVGLF
HZ~
IH2
IHE
J1W
J5H
K-O
KOM
L7B
M29
M41
MO0
N9A
O-L
O9-
OAUVE
OG0
OS0
OZT
P-8
P-9
P2P
PC.
PQQKQ
PROAC
Q38
R2-
ROL
RPZ
SAE
SDF
SDG
SDP
SEL
SES
SEW
SJN
SPCBC
SSH
SSZ
SV3
T5K
UGJ
UHS
UNMZH
UV1
WUQ
X7M
Z5R
ZGI
~G-
3V.
7X7
8FI
AACTN
AFCTW
AFKRA
AFKWA
AJOXV
AMFUW
AZQEC
BENPR
FYUFA
GUQSH
M1P
M2O
RIG
AAIAV
ABLVK
ABYKQ
AHPSJ
AJBFU
EFLBG
LCYCR
ZA5
AAYXX
AGRNS
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
K9.
7X8
ID FETCH-LOGICAL-c502t-945a0acda47f96eebf522b09f8f43eef6d14e350f31e590caa1395e5f56b95623
IEDL.DBID .~1
ISSN 0046-8177
1532-8392
IngestDate Thu Jul 10 23:49:35 EDT 2025
Fri Jul 25 05:13:46 EDT 2025
Wed Feb 19 02:41:09 EST 2025
Tue Jul 01 02:24:23 EDT 2025
Thu Apr 24 23:08:20 EDT 2025
Fri Feb 23 02:24:39 EST 2024
Tue Feb 25 19:55:52 EST 2025
Tue Aug 26 16:56:46 EDT 2025
IsPeerReviewed true
IsScholarly true
Keywords Hepatic tumors
Cholangiolocellular carcinoma
Isocitrate dehydrogenase
Bile ducts
Cholangiocarcinoma
Language English
License Copyright © 2017. Published by Elsevier Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c502t-945a0acda47f96eebf522b09f8f43eef6d14e350f31e590caa1395e5f56b95623
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
PMID 28431889
PQID 1912664763
PQPubID 105547
PageCount 10
ParticipantIDs proquest_miscellaneous_1891148420
proquest_journals_1912664763
pubmed_primary_28431889
crossref_primary_10_1016_j_humpath_2017_01_016
crossref_citationtrail_10_1016_j_humpath_2017_01_016
elsevier_sciencedirect_doi_10_1016_j_humpath_2017_01_016
elsevier_clinicalkeyesjournals_1_s2_0_S0046817717301168
elsevier_clinicalkey_doi_10_1016_j_humpath_2017_01_016
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-06-01
PublicationDateYYYYMMDD 2017-06-01
PublicationDate_xml – month: 06
  year: 2017
  text: 2017-06-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Philadelphia
PublicationTitle Human pathology
PublicationTitleAlternate Hum Pathol
PublicationYear 2017
Publisher Elsevier Inc
Elsevier Limited
Publisher_xml – name: Elsevier Inc
– name: Elsevier Limited
References Tyson, El-Serag (bb0010) 2011; 54
Edge, Byrd, Compton, Fritz, Greene, Trotti (bb0105) 2010
Ariizumi, Yamamoto (bb0075) 2015; 45
Nakanuma, Curado, Franceschi (bb0060) 2010
Batts, Ludwig (bb0110) 1995; 19
de Jong, Nathan, Sotiropoulos (bb0020) 2011; 9
Wang, Li, Xia (bb0015) 2013; 31
Aishima, Oda (bb0080) 2015; 22
Charbel, Al-Kawas (bb0005) 2011; 13
Steiner, Higginson (bb0025) 1959; 12
Komuta, Spee, Vander (bb0035) 2008; 47
Theise, Nakashima, Park, Nakanuma (bb0040) 2010
Ariizumi, Kotera, Katagiri (bb0050) 2014; 21
Rocha, Lee, Katabi (bb0070) 2012; 56
Wang, Dong, Zhang (bb0120) 2013; 32
Akiba, Nakashima, Hattori (bb0115) 2013; 37
Liau, Tsai, Yuan, Chang, Lee, Jeng (bb0030) 2014; 27
Shimada, Sano, Nara (bb0065) 2009; 145
Shibahara, Hayashi, Misumi (bb0045) 2016; 40
Saha, Parachoniak, Ghanta (bb0095) 2014; 513
Iavarone, Piscaglia, Vavassori (bb0100) 2013; 58
Komuta, Govaere, Vandecaveye (bb0055) 2012; 55
Borger, Tanabe, Fan (bb0085) 2012; 17
Kipp, Voss, Kerr (bb0090) 2012; 43
Saha (10.1016/j.humpath.2017.01.016_bb0095) 2014; 513
Rocha (10.1016/j.humpath.2017.01.016_bb0070) 2012; 56
Aishima (10.1016/j.humpath.2017.01.016_bb0080) 2015; 22
Charbel (10.1016/j.humpath.2017.01.016_bb0005) 2011; 13
Ariizumi (10.1016/j.humpath.2017.01.016_bb0075) 2015; 45
Wang (10.1016/j.humpath.2017.01.016_bb0015) 2013; 31
Shimada (10.1016/j.humpath.2017.01.016_bb0065) 2009; 145
Liau (10.1016/j.humpath.2017.01.016_bb0030) 2014; 27
Iavarone (10.1016/j.humpath.2017.01.016_bb0100) 2013; 58
Akiba (10.1016/j.humpath.2017.01.016_bb0115) 2013; 37
Steiner (10.1016/j.humpath.2017.01.016_bb0025) 1959; 12
Komuta (10.1016/j.humpath.2017.01.016_bb0055) 2012; 55
Batts (10.1016/j.humpath.2017.01.016_bb0110) 1995; 19
Theise (10.1016/j.humpath.2017.01.016_bb0040) 2010
Wang (10.1016/j.humpath.2017.01.016_bb0120) 2013; 32
de Jong (10.1016/j.humpath.2017.01.016_bb0020) 2011; 9
Nakanuma (10.1016/j.humpath.2017.01.016_bb0060) 2010
Kipp (10.1016/j.humpath.2017.01.016_bb0090) 2012; 43
Tyson (10.1016/j.humpath.2017.01.016_bb0010) 2011; 54
Ariizumi (10.1016/j.humpath.2017.01.016_bb0050) 2014; 21
Komuta (10.1016/j.humpath.2017.01.016_bb0035) 2008; 47
Borger (10.1016/j.humpath.2017.01.016_bb0085) 2012; 17
Shibahara (10.1016/j.humpath.2017.01.016_bb0045) 2016; 40
Edge (10.1016/j.humpath.2017.01.016_bb0105) 2010
References_xml – volume: 43
  start-page: 1552
  year: 2012
  end-page: 1558
  ident: bb0090
  article-title: Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
  publication-title: H
– volume: 31
  start-page: 1188
  year: 2013
  end-page: 1195
  ident: bb0015
  article-title: Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy
  publication-title: J Clin Oncol
– volume: 513
  start-page: 110
  year: 2014
  end-page: 114
  ident: bb0095
  article-title: Mutant
  publication-title: Nature
– volume: 37
  start-page: 496
  year: 2013
  end-page: 505
  ident: bb0115
  article-title: Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification
  publication-title: Am J Surg Pathol
– volume: 47
  start-page: 1544
  year: 2008
  end-page: 1556
  ident: bb0035
  article-title: Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin
  publication-title: Hepatology
– volume: 54
  start-page: 173
  year: 2011
  end-page: 184
  ident: bb0010
  article-title: Risk factors for cholangiocarcinoma
  publication-title: Hepatology
– volume: 21
  start-page: S451
  year: 2014
  end-page: S458
  ident: bb0050
  article-title: Long-term survival of patients with cholangiolocellular carcinoma after curative hepatectomy
  publication-title: Ann Surg Oncol
– volume: 12
  start-page: 753
  year: 1959
  end-page: 759
  ident: bb0025
  article-title: Cholangiolocellular carcinoma of the liver
  publication-title: Cancer
– volume: 40
  start-page: 608
  year: 2016
  end-page: 616
  ident: bb0045
  article-title: Clinicopathologic characteristics of hepatocellular carcinoma with reactive ductule-like components, a subset of liver cancer currently classified as combined hepatocellular-cholangiocarcinoma with stem cell features, typical subtype
  publication-title: Am J Surg Pathol
– volume: 45
  start-page: 682
  year: 2015
  end-page: 687
  ident: bb0075
  article-title: Intrahepatic cholangiocarcinoma and cholangiolocellular carcinoma in cirrhosis and chronic viral hepatitis
  publication-title: Surg Today
– volume: 55
  start-page: 1876
  year: 2012
  end-page: 1888
  ident: bb0055
  article-title: Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes
  publication-title: Hepatology
– volume: 56
  start-page: 1352
  year: 2012
  end-page: 1360
  ident: bb0070
  article-title: Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas
  publication-title: Hepatology
– volume: 19
  start-page: 1409
  year: 1995
  end-page: 1417
  ident: bb0110
  article-title: Chronic hepatitis: an update on terminology and reporting
  publication-title: Am J Surg Pathol
– volume: 145
  start-page: 411
  year: 2009
  end-page: 416
  ident: bb0065
  article-title: Therapeutic value of lymph node dissection during hepatectomy in patients with intrahepatic cholangiocellular carcinoma with negative lymph node involvement
  publication-title: Surgery
– volume: 17
  start-page: 72
  year: 2012
  end-page: 79
  ident: bb0085
  article-title: Frequent mutation of isocitrate dehydrogenase (
  publication-title: Oncologist
– start-page: 217
  year: 2010
  end-page: 224
  ident: bb0060
  article-title: Intrahepatic cholangiocarcinoma
  publication-title: WHO classification of tumours of the digestive system
– volume: 32
  start-page: 3091
  year: 2013
  end-page: 3100
  ident: bb0120
  article-title: Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas
  publication-title: Oncogene
– volume: 9
  start-page: 3140
  year: 2011
  end-page: 3145
  ident: bb0020
  article-title: Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment
  publication-title: J Clin Oncol
– start-page: 247
  year: 2010
  end-page: 254
  ident: bb0105
  article-title: AJCC cancer staging manual
– volume: 13
  start-page: 182
  year: 2011
  end-page: 187
  ident: bb0005
  article-title: Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis
  publication-title: Curr Gastroenterol Rep
– start-page: 225
  year: 2010
  end-page: 227
  ident: bb0040
  article-title: Combined hepatocellular-cholangiocarcinoma
  publication-title: WHO classification of tumours of the digestive system
– volume: 22
  start-page: 94
  year: 2015
  end-page: 100
  ident: bb0080
  article-title: Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type
  publication-title: J Hepatobiliary Pancreat Sci
– volume: 27
  start-page: 1163
  year: 2014
  end-page: 1173
  ident: bb0030
  article-title: Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features
  publication-title: Mod Pathol
– volume: 58
  start-page: 1188
  year: 2013
  end-page: 1193
  ident: bb0100
  article-title: Contrast-enhanced CT scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis
  publication-title: J Hepatol
– volume: 56
  start-page: 1352
  year: 2012
  ident: 10.1016/j.humpath.2017.01.016_bb0070
  article-title: Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas
  publication-title: Hepatology
  doi: 10.1002/hep.25786
– volume: 31
  start-page: 1188
  year: 2013
  ident: 10.1016/j.humpath.2017.01.016_bb0015
  article-title: Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.41.5984
– volume: 43
  start-page: 1552
  year: 2012
  ident: 10.1016/j.humpath.2017.01.016_bb0090
  article-title: Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
  publication-title: Hum Pathol
  doi: 10.1016/j.humpath.2011.12.007
– volume: 13
  start-page: 182
  year: 2011
  ident: 10.1016/j.humpath.2017.01.016_bb0005
  article-title: Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis
  publication-title: Curr Gastroenterol Rep
  doi: 10.1007/s11894-011-0178-8
– volume: 27
  start-page: 1163
  year: 2014
  ident: 10.1016/j.humpath.2017.01.016_bb0030
  article-title: Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.2013.241
– volume: 9
  start-page: 3140
  year: 2011
  ident: 10.1016/j.humpath.2017.01.016_bb0020
  article-title: Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.35.6519
– volume: 32
  start-page: 3091
  year: 2013
  ident: 10.1016/j.humpath.2017.01.016_bb0120
  article-title: Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas
  publication-title: Oncogene
  doi: 10.1038/onc.2012.315
– volume: 54
  start-page: 173
  year: 2011
  ident: 10.1016/j.humpath.2017.01.016_bb0010
  article-title: Risk factors for cholangiocarcinoma
  publication-title: Hepatology
  doi: 10.1002/hep.24351
– volume: 17
  start-page: 72
  year: 2012
  ident: 10.1016/j.humpath.2017.01.016_bb0085
  article-title: Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2011-0386
– volume: 21
  start-page: S451
  issue: Suppl. 3
  year: 2014
  ident: 10.1016/j.humpath.2017.01.016_bb0050
  article-title: Long-term survival of patients with cholangiolocellular carcinoma after curative hepatectomy
  publication-title: Ann Surg Oncol
  doi: 10.1245/s10434-014-3582-0
– volume: 45
  start-page: 682
  year: 2015
  ident: 10.1016/j.humpath.2017.01.016_bb0075
  article-title: Intrahepatic cholangiocarcinoma and cholangiolocellular carcinoma in cirrhosis and chronic viral hepatitis
  publication-title: Surg Today
  doi: 10.1007/s00595-014-1031-0
– volume: 145
  start-page: 411
  year: 2009
  ident: 10.1016/j.humpath.2017.01.016_bb0065
  article-title: Therapeutic value of lymph node dissection during hepatectomy in patients with intrahepatic cholangiocellular carcinoma with negative lymph node involvement
  publication-title: Surgery
  doi: 10.1016/j.surg.2008.11.010
– volume: 40
  start-page: 608
  year: 2016
  ident: 10.1016/j.humpath.2017.01.016_bb0045
  article-title: Clinicopathologic characteristics of hepatocellular carcinoma with reactive ductule-like components, a subset of liver cancer currently classified as combined hepatocellular-cholangiocarcinoma with stem cell features, typical subtype
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0000000000000579
– start-page: 225
  year: 2010
  ident: 10.1016/j.humpath.2017.01.016_bb0040
  article-title: Combined hepatocellular-cholangiocarcinoma
– volume: 12
  start-page: 753
  year: 1959
  ident: 10.1016/j.humpath.2017.01.016_bb0025
  article-title: Cholangiolocellular carcinoma of the liver
  publication-title: Cancer
  doi: 10.1002/1097-0142(195907/08)12:4<753::AID-CNCR2820120420>3.0.CO;2-L
– volume: 55
  start-page: 1876
  year: 2012
  ident: 10.1016/j.humpath.2017.01.016_bb0055
  article-title: Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes
  publication-title: Hepatology
  doi: 10.1002/hep.25595
– start-page: 217
  year: 2010
  ident: 10.1016/j.humpath.2017.01.016_bb0060
  article-title: Intrahepatic cholangiocarcinoma
– volume: 22
  start-page: 94
  year: 2015
  ident: 10.1016/j.humpath.2017.01.016_bb0080
  article-title: Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type
  publication-title: J Hepatobiliary Pancreat Sci
  doi: 10.1002/jhbp.154
– start-page: 247
  year: 2010
  ident: 10.1016/j.humpath.2017.01.016_bb0105
– volume: 37
  start-page: 496
  year: 2013
  ident: 10.1016/j.humpath.2017.01.016_bb0115
  article-title: Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0b013e31827332b0
– volume: 19
  start-page: 1409
  year: 1995
  ident: 10.1016/j.humpath.2017.01.016_bb0110
  article-title: Chronic hepatitis: an update on terminology and reporting
  publication-title: Am J Surg Pathol
  doi: 10.1097/00000478-199512000-00007
– volume: 58
  start-page: 1188
  year: 2013
  ident: 10.1016/j.humpath.2017.01.016_bb0100
  article-title: Contrast-enhanced CT scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2013.02.013
– volume: 47
  start-page: 1544
  year: 2008
  ident: 10.1016/j.humpath.2017.01.016_bb0035
  article-title: Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin
  publication-title: Hepatology
  doi: 10.1002/hep.22238
– volume: 513
  start-page: 110
  year: 2014
  ident: 10.1016/j.humpath.2017.01.016_bb0095
  article-title: Mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer
  publication-title: Nature
  doi: 10.1038/nature13441
SSID ssj0011545
Score 2.3369002
Snippet Cholangiolocellular carcinoma is a type of intrahepatic cholangiocarcinoma (ICC). According to the 2010 World Health Organization classification, this...
Summary Cholangiolocellular carcinoma is a type of intrahepatic cholangiocarcinoma (ICC). According to the 2010 World Health Organization classification, this...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 118
SubjectTerms Adult
Aged
Aged, 80 and over
Bile
Bile Duct Neoplasms - diagnosis
Bile Duct Neoplasms - diagnostic imaging
Bile Duct Neoplasms - genetics
Bile Duct Neoplasms - pathology
Bile ducts
Biomarkers, Tumor - genetics
Biopsy
Carcinoma, Hepatocellular - diagnosis
Carcinoma, Hepatocellular - diagnostic imaging
Carcinoma, Hepatocellular - genetics
Carcinoma, Hepatocellular - pathology
Cell Proliferation
Cholangiocarcinoma
Cholangiocarcinoma - diagnosis
Cholangiocarcinoma - diagnostic imaging
Cholangiocarcinoma - genetics
Cholangiocarcinoma - pathology
Cholangiolocellular carcinoma
Classification
Dehydrogenases
Digestive system
DNA Mutational Analysis
Female
Hepatectomy
Hepatic tumors
Hepatitis
Hepatology
Humans
Immunohistochemistry
Isocitrate dehydrogenase
Isocitrate Dehydrogenase - genetics
Kaplan-Meier Estimate
Laboratories
Liver cancer
Liver Neoplasms - diagnosis
Liver Neoplasms - diagnostic imaging
Liver Neoplasms - genetics
Liver Neoplasms - pathology
Lymphatic system
Male
Medical prognosis
Medical records
Middle Aged
Molecular Diagnostic Techniques
Mutation
Neoplasm Invasiveness
Neoplasms, Complex and Mixed - diagnosis
Neoplasms, Complex and Mixed - diagnostic imaging
Neoplasms, Complex and Mixed - genetics
Neoplasms, Complex and Mixed - pathology
Neoplastic Stem Cells - pathology
Pathology
Patients
Predictive Value of Tests
Proportional Hazards Models
Stem cells
Studies
Surgery
Time Factors
Tomography, X-Ray Computed
Treatment Outcome
Tumor Burden
Tumorigenesis
Tumors
Viral infections
Title Clinicopathological, radiologic, and molecular study of 23 combined hepatocellular-cholangiocarcinomas with stem cell features, cholangiolocellular type
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0046817717301168
https://www.clinicalkey.es/playcontent/1-s2.0-S0046817717301168
https://dx.doi.org/10.1016/j.humpath.2017.01.016
https://www.ncbi.nlm.nih.gov/pubmed/28431889
https://www.proquest.com/docview/1912664763
https://www.proquest.com/docview/1891148420
Volume 64
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swELcQSNNepsG-ugHypD02bZzYTvyIEKhQwcM0NN4sJzmPIkhQW173d-zP3V3iBE1jYkKqVKW9i6O7y_ln-z4Y-4IQVEMCcZQhdoikQF3kZSWitBQl5CAqV9A-5Nm5nl3I00t1ucEO-1wYCqsMvr_z6a23Dr9MgzSnd4sF5fhKnYuMjpHpNIESfqXMyMonP4cwD6o203UxkDoi6ocsnun15ApFhkCLIryytnontT1_fH76F_5s56Hj1-xVAJD8oHvGbbYB9Q57cRaOyN-wX12lz4ZG7B3bmC9dteiuxtzVFb_tu-Lytr4sbzxPUo5CwIUyVPwKJ6l1Q5v6RBO1C-D6xwLnvSWOQiFFnDZwOVWB5kTGPbQVQldjPhDfDDfgtNH7ll0cH307nEWh_UJUqjhZR0YqF7uycjLzRgMUHrFaERufe5kCeF0JCamKfSpAmbh0DtGkAuWVLgzBqndss25q-MB4WkCiq8IA0kpTmFxlvt0_QTCXIiQdMdkL3ZahNjm1yLixfRDatQ26sqQrGwv86BGbDGx3XXGOpxh0r1HbZ56ir7Q4fTzFmD3GCKvwxq-ssKvExvYvqxyxfOD8w7D_Z9Dd3ujswzhGIKZCO09H7PPwN_oEUqmroblHmtzQMlcmKNj3nbEO8kE4gm48Nx-f_1yf2Eu66gLmdtnmenkPewjN1sV---7ts62Dk_nsnL7nX7_PfwOQBDzX
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fT9swELdYkba9TPvLytjmSXtsaJzYTvyI0FAZtE8g8WY5yXkUsQS15bvs43KXOEHTmJgm5aXJXR3dOXc_353PjH1FCKohgTjKEDtEUqAu8rISUVqKEnIQlSsoDjlf6Nm5_H6hLrbYYb8Xhsoqg-3vbHprrcOdaZDm9Ga5pD2-UuciozQyZRPyJ2ybulOpEds-OD6ZLYZkAqGELtGsI2K438gzvdq_RKkh1qIir6xt4Eknnz_sov4GQVtXdPSSvQgYkh90r_mKbUH9mj2dhyz5G_ara_bZ0Ii9bZvwlauW3a8Jd3XFf_YH4_K2xSxvPE9SjnLAtTJU_BL91KahuD7RRO0auP6xRNe3wlGoqohTDJdTI2hOZNxD2yR0PeED8fXwB5xivW_Z-dG3s8NZFE5giEoVJ5vISOViV1ZOZt5ogMIjXCti43MvUwCvKyEhVbFPBSgTl84hoFSgvNKFIWT1jo3qpob3jKcFJLoqDCCtNIXJVebbEAriuRRR6ZjJXui2DO3J6ZSMa9vXoV3ZoCtLurKxwEuP2f7AdtP153iMQfcatf3mUzSXFj3IY4zZQ4ywDh_92gq7Tmxs_5iYY5YPnL_N7X8ZdK-fdPZ-HCMQVkn0DGP2ZXiMZoFU6mpobpEmN7TSlQkKdqebrIN8EJGgJc_N7v-_12f2bHY2P7Wnx4uTD-w5Penq5_bYaLO6hY-I1DbFp_Al3gFWLD3l
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinicopathological%2C+radiologic%2C+and+molecular+study+of+23+combined+hepatocellular-cholangiocarcinomas+with+stem+cell+features%2C+cholangiolocellular+type&rft.jtitle=Human+pathology&rft.au=Chen%2C+Jun&rft.au=He%2C+Jian&rft.au=Deng%2C+Min&rft.au=Wu%2C+Hong-Yan&rft.date=2017-06-01&rft.eissn=1532-8392&rft.volume=64&rft.spage=118&rft_id=info:doi/10.1016%2Fj.humpath.2017.01.016&rft_id=info%3Apmid%2F28431889&rft.externalDocID=28431889
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00468177%2Fcov200h.gif